Development asset linked to PDS Biotechnology in public FDA and regional records.
biotech · Recurrent Head and Neck Cancer · Metastatic Head and Neck Cancer · PDSB
PDS Biotechnology
PDS Biotechnology Corp
PDS Biotechnology drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Princeton, USA HQ
2005 Founded
32 Employees
Public company Type
PDSB · NYSE Ticker
Company details
- Status
- Public
- HQ
- Princeton, USA
- Founded
- 2005
- Employees
- 32
- Programs
- 3
- Drugs
- 5
- Patents
- 11
PDS Biotechnology pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
PDS Biotechnology drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to PDS Biotechnology in public FDA and regional records.
-
Development asset linked to PDS Biotechnology in public FDA and regional records.
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to PDS Biotechnology in public FDA and regional records.